Skip to main content

Table 3 Vedolizumab therapy in 12 patients with IBD

From: Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease

ID Dosage in mg Duration of therapy at last follow up, weeks Response and outcome of therapy
CD01 250 36 Loss of response, discontinuation in week 37
CD02 300 64 No remission achieved, dosing interval 4 weeks, variable disease course, therapy ongoing
CD03 300 64 Remission after 14 weeks, variable disease course, therapy ongoing
CD04 300 36 Partial remission in week 14, loss of response, discontinuation in week 34
CD05 300 60 No remission achieved, variable disease course, therapy ongoing
CD06 200 16 Primary non-responder, discontinuation in week 22
CD07 300 8 Systemic allergic reaction at 2nd infusion, discontinuation
UC08 250 88 No remission achieved, variable disease course, therapy ongoing
UC09 150 96 Good response, remission, therapy ongoing
UC10 300 64 Total colectomy due to severe course of the disease 60 weeks after vedolizumab start
UC11 300 52 Good response, remission, therapy ongoing
IBD-U12 300 52 No remission achieved, variable disease course, therapy ongoing
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us